# Body image and GLP-1 medication trends in Brazil

> Live situation record from CLSTR: https://clstr.news/situations/impact-of-body-image-on-mental-health-in-brazil
> Updated: 2026-08-23T22:57:07.000Z. Sources: 77. Developments: 4.

Health experts and regulatory bodies in Brazil are intensifying warnings regarding the use of GLP-1 receptor agonists, such as semaglutide and tirzepatide, for weight loss. While effective for obesity, a systematic review of over 15,000 participants indicates that rapid weight loss via these ‘weight loss pens’ can lead to significant reductions in lean muscle mass.

Medical specialists, including the Brazilian Society of Pediatrics (SBP), have issued national alerts regarding unsupervised use among children and adolescents. Potential adverse effects for younger populations include growth and development deficits, dehydration, electrolyte imbalances, acute pancreatitis, and gallbladder issues. Experts warn that using these drugs for purely aesthetic purposes may trigger eating disorders like anorexia and bulimia, as well as anxiety and depression.

The SBP and the Brazilian Society of Endocrinology and Metabology (SBEM) emphasize that improper use can lead to significant loss of muscle mass and micronutrient deficiencies. To combat sarcopenia, endocrinologists recommend maintaining high protein intake alongside strength training. Specifically, endocrinologist Marcio Mancini suggests a protein intake of 1.2g/kg/day for healthy young individuals and 1.5g/kg/day for the elderly or those at risk of sarcopenia to mitigate the effects of intense appetite suppression and delayed gastric emptying.

Recent expert warnings reiterate that these drugs are medical treatments for conditions like obesity and type 2 diabetes, rather than supplements. Specialists note that weight loss after age 40 requires a more complex approach involving hormonal, metabolic, and nutritional considerations. Regulatory and market shifts continue as Anvisa prohibits unregistered products. The SBP advises against using clandestine or imported preparations lacking sanitary registration and recommends using the term ‘medications to treat obesity’ rather than ‘weight-loss pens’ to better recognize obesity as a chronic disease.

## Claims

- The Sociedade Brasileira de Pediatria (SBP) issued an alert regarding the use of GLP-1 receptor agonists by children and adolescents without medical supervision. (corroborated by 13 sources)
- Risks of unsupervised use include growth and development deficits, dehydration, electrolyte disturbances, muscle loss, acute pancreatitis, and gallbladder issues. (corroborated by 13 sources)
- Using these medications for aesthetic purposes can trigger eating disorders such as anorexia and bulimia, along with anxiety and depression. (corroborated by 13 sources)
- The medication's effect on appetite and stomach emptying can lead to insufficient protein and vitamin intake. (corroborated by 2 sources)
- Recommended protein intake is 1.2g/kg/day for healthy young people and 1.5g/kg/day for the elderly or those at risk of sarcopenia. (corroborated by 2 sources)

## Timeline

### 2026-08-23: Medical experts warn of risks from unsupervised GLP-1 weight-loss medication use

Medical experts and the SBP warn against the unsupervised use of GLP-1 weight-loss medications, citing risks of growth deficits, muscle loss, and eating disorders, especially in children and adolescents.

38 sources. https://clstr.news/cluster/glp-1-weight-loss-medications-pose-risks-to-children-and-adolescents

### 2026-08-21: Weight-loss medications pose risks of muscle loss and nutrient deficiency

Medical experts warn that unsupervised use of GLP-1 weight-loss medications can cause muscle loss, nutrient deficiencies, and facial sagging, necessitating high-protein diets and medical supervision.

26 sources. https://clstr.news/cluster/weight-loss-medications-linked-to-muscle-loss-and-facial-sagging

### 2026-08-13: Health experts warn of muscle loss and risks from weight loss medications

Experts warn of muscle mass loss and eating disorder risks linked to popular weight loss medications, while Anvisa bans unregistered products mimicking GLP-1 drugs.

18 sources. https://clstr.news/cluster/health-experts-discuss-body-image-and-post-weight-loss-surgical-requirements

### 2026-08-11: Extreme thinness impacts youth body image and mental health

Experts and psychoanalysts warn that extreme thinness in media can trigger eating disorders and dysfunctional body image comparison, especially among vulnerable adolescents.

2 sources. https://clstr.news/cluster/extreme-thinness-impacts-youth-body-image-and-mental-health

---
Cite as: Body image and GLP-1 medication trends in Brazil. CLSTR, https://clstr.news/situations/impact-of-body-image-on-mental-health-in-brazil